Acumen Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Acumen Pharmaceuticals, Inc. (ABOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 65.29 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 63.72K shares, a 130.11% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 1.56K shares, a 95.06% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 16.10K shares.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 75.40K shares, a 53.80% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 163.22K shares, a 1026.50% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 14.49K shares, a 81.86% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 79.87K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 63.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 65.29K shares 10-Q · filed 2026-08-12 | 65.29K shares derived: sum of 3 quarters · filed 2026-08-12 | 81.39K shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 1.56K shares 10-Q · filed 2026-05-12 | 1.56K shares derived: sum of 2 quarters · filed 2026-05-12 | 17.66K shares derived: sum of 3 quarters · filed 2026-05-12 | 45.35K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 16.10K shares derived: sum of 2 quarters · filed 2026-03-26 | 43.79K shares derived: sum of 3 quarters · filed 2026-03-26 | 75.40K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 16.10K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 43.79K shares derived: sum of 2 quarters · filed 2025-11-12 | 75.40K shares 10-Q · filed 2025-11-12 | 180.75K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 27.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 59.30K shares 10-Q · filed 2025-08-12 | 164.65K shares derived: sum of 3 quarters · filed 2025-08-12 | 164.65K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 31.61K shares 10-Q · filed 2025-05-13 | 136.96K shares derived: sum of 2 quarters · filed 2025-05-13 | 136.96K shares derived: sum of 3 quarters · filed 2025-05-13 | |
| 2024-12-31 | 105.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 105.35K shares derived: sum of 2 quarters · filed 2025-03-27 | 163.22K shares 10-K · filed 2025-03-27 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 57.87K shares 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | 57.87K shares 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 2.49K shares derived: sum of 2 quarters · filed 2024-03-26 | 14.49K shares 10-K · filed 2024-03-26 | |
| 2023-09-30 | 2.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 14.49K shares 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | 12.00K shares 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 46.72K shares derived: sum of 2 quarters · filed 2023-03-27 | 61.72K shares derived: sum of 3 quarters · filed 2023-03-27 | 79.87K shares 10-K · filed 2023-03-27 |
| 2022-09-30 | 46.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 61.72K shares derived: sum of 2 quarters · filed 2022-11-14 | 79.87K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 15.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 33.15K shares 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | 18.15K shares 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |